Biogen, Inc. (BIIB)
248.35
+4.42
(+1.81%)
USD |
NASDAQ |
Nov 06, 16:00
248.35
0.00 (0.00%)
After-Hours: 20:00
Biogen Total Long Term Debt (Quarterly) : 7.801B for Sept. 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 7.801B |
| June 30, 2026 | 8.355B |
| March 31, 2026 | 6.562B |
| December 31, 2025 | 6.577B |
| September 30, 2025 | 6.590B |
| June 30, 2025 | 6.595B |
| March 31, 2025 | 6.621B |
| December 31, 2024 | 6.630B |
| September 30, 2024 | 6.651B |
| June 30, 2024 | 6.660B |
| March 31, 2024 | 6.947B |
| December 31, 2023 | 7.338B |
| September 30, 2023 | 7.715B |
| June 30, 2023 | 6.589B |
| March 31, 2023 | 6.610B |
| December 31, 2022 | 6.614B |
| September 30, 2022 | 6.634B |
| June 30, 2022 | 7.551B |
| March 31, 2022 | 7.588B |
| December 31, 2021 | 7.604B |
| September 30, 2021 | 7.619B |
| June 30, 2021 | 7.633B |
| March 31, 2021 | 7.647B |
| December 31, 2020 | 7.828B |
| September 30, 2020 | 7.834B |
| Date | Value |
|---|---|
| June 30, 2020 | 7.839B |
| March 31, 2020 | 6.365B |
| December 31, 2019 | 6.368B |
| September 30, 2019 | 6.364B |
| June 30, 2019 | 6.372B |
| March 31, 2019 | 6.379B |
| December 31, 2018 | 5.936B |
| September 30, 2018 | 5.931B |
| June 30, 2018 | 5.928B |
| March 31, 2018 | 5.933B |
| December 31, 2017 | 5.938B |
| September 30, 2017 | 6.512B |
| June 30, 2017 | 6.514B |
| March 31, 2017 | 6.514B |
| December 31, 2016 | 6.517B |
| September 30, 2016 | 6.534B |
| June 30, 2016 | 6.543B |
| March 31, 2016 | 6.540B |
| December 31, 2015 | 6.526B |
| September 30, 2015 | 6.534B |
| June 30, 2015 | 579.47M |
| March 31, 2015 | 583.93M |
| December 31, 2014 | 585.20M |
| September 30, 2014 | 587.20M |
| June 30, 2014 | 589.48M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| AbbVie, Inc. | 80.90B |
| Gilead Sciences, Inc. | 26.23B |
| Amgen, Inc. | 54.01B |
| Regeneron Pharmaceuticals, Inc. | 2.707B |
| Eli Lilly & Co. | 49.50B |